Age (y.o.) | 70 (49–84) | 69 (39–77) | 0.520 | 67 (40–87) | 69 (44–78) | > 0.999 |
Gender (Male / Female) | 13 / 12 | 9 / 2 | 0.091 | 18 / 11 | 7 / 6 | 0.616 |
Type of Neoadjuvant therapy |
Chemotherapy | 17 (68.0%) | 8 (72.7%) | 0.777 | – | – | – |
Chemoradiotherapy | 8 (32.0%) | 3 (27.3%) | | | | |
PTPE | 4 (16.0%) | 2 (18.2%) | 0.871 | 8 (27.6%) | 4 (30.8%) | 0.833 |
Initial tumor marker |
CEA (ng/mL) | 3.7 (1.3–14.6) | 3.9 (0.9–16.3) | 0.685 | 2.9 (0.6–38.4) | 2.6 (0.7–28.0) | 0.936 |
CA19–9 (U/mL) | 61.5 (1.0–7898) | 140.3 (1.0–1325) | 0.435 | 87.5 (7.0–1115.7) | 65.1 (1.0–9278) | 0.872 |
Preoperative tumor marker |
CEA (ng/mL) | 2.6 (0.9–9.6) | 3.6 (1.1–24.4) | 0.151 | 3.0 (0.7–32.2) | 2.6 (0.5–32.3) | 0.788 |
CA19–9 (U/mL) | 33.2 (1.0–11,659) | 151.3 (1.0–1158) | 0.086 | 67.3 (13.7–977.2) | 65.1 (1.0–9278) | 0.936 |
Type of liver resectiona | | | | | | 0.114 |
No liver resection | 0 | 0 | | 5 (17.2%) | 0 | |
S1,5,6,7,8 | 9 (36.0%) | 3 (27.3%) | | 10 (34.5%) | 5 (38.5%) | |
S1,4,5,6,7,8 | 1 (4.0%) | 1 (9.1%) | | 2 (6.9%) | 3 (23.1%) | |
S1,2,3,4 | 9 (36.0%) | 6 (54.5%) | | 7 (24.1%) | 4 (30.8%) | |
S1,2,3,4,5,8 | 3 (12.0%) | 1 (9.1%) | | 0 | 1 (7.7%) | |
Others | 3 (12.0%) | 0 | | 5 (17.2%) | 0 | |
HPD | 0 | 1 (9.1%) | 0.126 | 3 (10.3%) | 0 | 0.229 |
Combined HA and/or PV resection | 12 (48.0%) | 10 (90.9%) | 0.015 | 11 (37.9%) | 6 (46.2%) | 0.616 |
Operation time (min) | 625 (383–965) | 672 (422–972) | 0.261 | 597 (403–1030) | 610 (435–746) | 0.914 |
Blood loss (ml) | 2212 (505–6916) | 2170 (1459–6012) | 0.612 | 1964 (166–9907) | 1830 (587–3870) | 0.727 |
Histological type |
G1, 2 / G3 | 25 / 0 (0%) | 6 / 5 (45.5%) | < 0.001 | 26 / 3 (10.3%) | 12 / 1 (7.7%) | 0.787 |
UICC 8th |
pT: T0–3 / T4 | 19 / 6 (24.0%) | 4 / 7 (63.6%) | 0.023 | 23 / 6 (20.7%) | 8 / 5 (38.5%) | 0.226 |
pN: N0 / N1–2 | 17 / 8 (32.0%) | 3 / 8 (72.7%) | 0.023 | 16 /13 (44.8%) | 4 / 9 (69.2%) | 0.143 |
M: M0 / M1a | 25 / 0 (0%) | 8 / 3 (27.3%) | 0.006 | 28 / 1 (3.4%) | 11 / 2 (15.4%) | 0.165 |
Residual tumor status |
R0 / R1 / R2 (M1 / margin positive) | 17 / 6 / 2 (0 / 2) | 6 / 1 / 4 (3 / 1) | 0.092 | 21 / 5 / 3 (1 / 2) | 9 / 2 / 2 (2 / 0) | 0.895 |
Postoperative hospital stay (days) | 45 (13–161) | 37 (17–136) | 0.308 | 49 (25–117) | 56 (18–325) | 0.374 |
Postoperative complication ≥ grade IIIb | 13 (52.0%) | 6 (54.5%) | 0.888 | 9 (31.0%) | 4 (30.8%) | 0.986 |
Postoperative chemotherapy | 19 (76.0%) | 9 (81.8%) | 0.699 | 18 (62.1%) | 10 (76.9%) | 0.345 |